What You Should Know:
– Clarivate Plc, a provider of trusted information and insights, today unveiled its highly anticipated 2024 Drugs to Watch report, shining a spotlight on 13 cutting-edge therapeutics poised to revolutionize healthcare in the coming year.
– These promising drugs span a diverse range of conditions, from debilitating diseases like sickle cell anemia and multiple myeloma to common ailments like chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
Top 13 Drugs to Watch in 2024
The 2024 Drugs to Watch, are:
– Aflibercept (high dose): Less frequent injections for treating AMD, DME, and DR, potentially reducing treatment burden.
– Budesonide (TARPEYO®/Kinpeygo®/Nefecon): Improved treatment for primary immunoglobulin A (IgA) nephropathy with better safety profile than conventional corticosteroids.
– Datopotamab deruxtecan (Dato-DXd): Potential best-in-class TROP2-targeted ADC for breast cancer and non-small cell lung cancer.
– Efanesoctocog alfa (ALTUVIIIO™/BIVV001): First once-weekly factor VIII replacement therapy for hemophilia A, offering improved convenience.
– Ensifentrine (RPL554): First inhaled dual PDE3 and PDE4 inhibitor for COPD, potentially reducing exacerbations with fewer side effects.
– Exagamglogene autotemcel (CASGEVY™ /exa-cel) and lovotibeglogene autotemcel (LYFGENIA™/lovo-cel): Groundbreaking gene-editing therapies for sickle cell disease and beta-thalassemia, offering potential cures.
– Mirikizumab (Omvoh™/ LY-3074828): First-in-class therapy for ulcerative colitis and potential third-in-class option for Crohn’s disease.
– Niraparib + abiraterone acetate (AKEEGA™): First dual-action tablet for deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
– RSVpreF (ABRYSVO™/PF-06928316) and RSVpreF3 (AREXVY/GSK-3844766A): First RSV vaccines for infants and older adults, addressing a major public health concern.
– Talquetamab (TALVEY™): First-in-class bispecific antibody for multiple myeloma, offering a new treatment option for heavily pretreated patients.
– Zolbetuximab (IMAB362): First-in-class claudin 18.2 inhibitor for HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, addressing a significant unmet need.
Beyond the Drugs
The report also highlights the growing influence of new technologies like CRISPR-Cas9 gene editing and AI/ML in the drug development process. These tools hold immense potential to accelerate innovation and bring life-saving therapies to patients faster.
“This year’s Drugs to Watch report showcases the incredible advancements taking place across the pharmaceutical landscape,” says Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare at Clarivate. “New modalities like antibody drug conjugates and AI-powered tools are fueling medical breakthroughs, offering hope to patients with previously unmet needs.”
